Evelo Biosciences, Inc. (NASDAQ:EVLO) Expected to Post Earnings of -$0.53 Per Share

Wall Street analysts expect Evelo Biosciences, Inc. (NASDAQ:EVLO) to report ($0.53) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Evelo Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.60) and the highest estimate coming in at ($0.45). Evelo Biosciences reported earnings of ($0.45) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 17.8%. The firm is scheduled to announce its next quarterly earnings results on Thursday, November 4th.

On average, analysts expect that Evelo Biosciences will report full year earnings of ($2.24) per share for the current financial year, with EPS estimates ranging from ($2.27) to ($2.20). For the next financial year, analysts anticipate that the company will post earnings of ($2.01) per share, with EPS estimates ranging from ($2.20) to ($1.91). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Evelo Biosciences.

Evelo Biosciences (NASDAQ:EVLO) last issued its earnings results on Wednesday, July 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.01.

EVLO has been the topic of several research reports. Zacks Investment Research lowered shares of Evelo Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 29th. Cantor Fitzgerald began coverage on shares of Evelo Biosciences in a research report on Wednesday, June 23rd. They set an “overweight” rating and a $28.00 target price on the stock. JMP Securities raised their target price on shares of Evelo Biosciences from $36.00 to $38.00 and gave the stock a “market outperform” rating in a research report on Wednesday, June 23rd. Finally, Chardan Capital decreased their target price on shares of Evelo Biosciences from $15.00 to $12.00 and set a “neutral” rating on the stock in a research report on Friday, July 30th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $20.33.

Shares of EVLO stock traded up $0.21 during trading hours on Wednesday, hitting $6.99. The company’s stock had a trading volume of 30,320 shares, compared to its average volume of 217,665. The business has a fifty day moving average of $10.28 and a 200-day moving average of $11.66. The stock has a market cap of $373.25 million, a price-to-earnings ratio of -3.36 and a beta of 1.29. Evelo Biosciences has a twelve month low of $3.82 and a twelve month high of $19.93. The company has a current ratio of 6.38, a quick ratio of 6.38 and a debt-to-equity ratio of 0.75.

Several institutional investors and hedge funds have recently made changes to their positions in EVLO. Meeder Asset Management Inc. purchased a new position in shares of Evelo Biosciences in the 1st quarter valued at $28,000. Metropolitan Life Insurance Co NY purchased a new stake in Evelo Biosciences during the 2nd quarter worth $123,000. Cresset Asset Management LLC purchased a new stake in Evelo Biosciences during the 2nd quarter worth $137,000. OLD Mission Capital LLC purchased a new stake in Evelo Biosciences during the 2nd quarter worth $138,000. Finally, American International Group Inc. grew its holdings in Evelo Biosciences by 15.5% during the 1st quarter. American International Group Inc. now owns 13,422 shares of the company’s stock worth $144,000 after acquiring an additional 1,801 shares in the last quarter. Institutional investors own 85.44% of the company’s stock.

Evelo Biosciences Company Profile

Evelo Biosciences, Inc operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases; EDP2939 for inflammation; and EDP1908 for oncology. The company was founded by Noubar B.

Recommended Story: What is the S&P/ASX 200 Index?

Get a free copy of the Zacks research report on Evelo Biosciences (EVLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evelo Biosciences (NASDAQ:EVLO)

Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.